更新于：2024-11-07
Hydrochlorothiazide
氢氯噻嗪
更新于：2024-11-07
概要
基本信息
简介氢氯噻嗪是一种小分子药物，作用于噻嗪类敏感氯化钠协同转运蛋白，是噻嗪类敏感氯化钠协同转运蛋白抑制剂。它的适应症包括尿崩症、水肿、高血压和肾结石等。氢氯噻嗪最初由诺华制药公司研发，并于1959年2月12日获得首次批准。该药物通过抑制NCC，减少肾脏中的钠重吸收，从而促进尿液排泄和水分排出，达到利尿的效果。此外，它还可以降低血压和防止肾结石形成。虽然氢氯噻嗪可以缓解症状，但也存在一些不良反应，如低钾血症、头晕、乏力等，需要在医生的指导下使用。总体而言，氢氯噻嗪是一种常用的利尿药和降压药，对多种疾病的治疗具有重要作用。 |
药物类型 小分子化药 |
别名 HCTZ、Hydrochlorothiazide (JP17/USP/INN)、氢氯噻嗪微片 + [10] |
靶点 |
作用机制 NCC抑制剂(噻嗪类敏感氯化钠协同转运蛋白抑制剂) |
非在研适应症 |
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (1959-02-12), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构
分子式C7H8ClN3O4S2 |
InChIKeyJZUFKLXOESDKRF-UHFFFAOYSA-N |
CAS号58-93-5 |
关联
244
项与 氢氯噻嗪 相关的临床试验Randomized, Double-blind, Crossover Trial Assessing the Efficacy of Indapamide and Chlorthalidone Compared to Hydrochlorothiazide for the Reduction of Urine Supersaturation for Kidney Stone Prevention
Clinical study of midapril hydrochloride combined with hydrochlorothiazide in the treatment of essential hypertension
A Prospective Randomised Control Trial To Study EfficacyAnd Safety Of Thiazide Diuretic In Subjects With Idiopathic Hypoparathyroidism - Nil
100 项与 氢氯噻嗪 相关的临床结果
登录后查看更多信息
100 项与 氢氯噻嗪 相关的转化医学
登录后查看更多信息
100 项与 氢氯噻嗪 相关的专利（医药）
登录后查看更多信息
7,563
项与 氢氯噻嗪 相关的文献（医药）2025-01-01JOURNAL OF ETHNOPHARMACOLOGY
Antiurolithic activity of Zaleya pentandra (L.) C Jeffrey in ethylene glycol-induced calcium oxalate crystal rat model; A scientific validation of traditional use for kidney stone prevention
Article
作者: Akhtar, Muhammad Furqan ; Anwar, Fareeha ; Riaz, Muhammad ; Khan, Aslam ; William, Sumaira ; khan, Aslam ; Ahmad, Rizwan
ETHNOPHARMACOLOGICAL RELEVANCE:
Traditional herbal remedies have been used for treating nephrolithiasis, but the relevant scientific evidence is limited. Zaleya pentandra (L.) C. Jeffrey is traditionally used for the prevention of kidney stones in various cultures. However, its efficacy has not been scientifically studied.
AIM OF THE STUDY:
This study aimed to investigate the antiurolithic activity of Zaleya pentandra, and validate its traditional used for preventing kidney stones.
MATERIALS AND METHODS:
The crude ethanolic extract of Z. pentandra (Zp.Crd) was evaluated through in vitro and in vivo studies. In vitro experiments assessed its impact on crystal count and morphology in metastable calcium oxalate solutions. In vivo studies involved diuretic and ethylene glycol-induced calcium oxalate crystal formation in male Wistar rats.
RESULTS:
Zp.Crd transforms calcium oxalate crystals from harmful calcium oxalate monohydrate (COM) to calcium oxalate dihydrate (COD). In vivo, Zp.Crd exhibited dose-dependent (30-300 mg/kg) diuretic activity in rats by significantly increasing urinary sodium (Na+) and potassium (K+) excretion, similar to the standard diuretic hydrochlorothiazide (HCT). In the urolithiasis model, Zp.Crd exhibited dose-dependent antiurolithic effects by reducing kidney crystals and significantly altering lithogenic factors induced by ethylene glycol, including crystalluria, oxaluria, calcium, creatinine, and urea, in the urine and serum of treated rats. Zp.Crd also exhibited antioxidant effects, effectively combating oxidative lithogenic stress in rats.
CONCLUSION:
Zp.Crd has been shown to demonstrate antiurolithic activity against CaOx stones through CaOx crystal inhibition, diuretic activity, antioxidant properties, hypocalciuric effects, and hypercitrauric actions. The findings underscore Zp.Crd's potential as a viable alternative or supplemental therapy to current urolithiasis treatments, paving the door for further clinical trials and its inclusion into modern medical practices.
2024-12-31RENAL FAILURE
Identification of kidney-related medications using AI from self-captured pill images
Article
作者: Cheungpasitporn, Wisit ; Barreto, Erin F. ; Sheikh, Mohammad S. ; Suppadungsuk, Supawadee ; Qureshi, Fawad ; Miao, Jing ; Thongprayoon, Charat ; Kashani, Kianoush B. ; Mao, Michael A. ; Pham, Justin H. ; Dreesman, Benjamin ; Craici, Iasmina M.
INTRODUCTION:
ChatGPT, a state-of-the-art large language model, has shown potential in analyzing images and providing accurate information. This study aimed to explore ChatGPT-4 as a tool for identifying commonly prescribed nephrology medications across different versions and testing dates.
METHODS:
25 nephrology medications were obtained from an institutional pharmacy. High-quality images of each medication were captured using an iPhone 13 Pro Max and uploaded to ChatGPT-4 with the query, 'What is this medication?' The accuracy of ChatGPT-4's responses was assessed for medication name, dosage, and imprint. The process was repeated after 2 weeks to evaluate consistency across different versions, including GPT-4, GPT-4 Legacy, and GPT-4.Ø.
RESULTS:
ChatGPT-4 correctly identified 22 out of 25 (88%) medications across all versions. However, it misidentified Hydrochlorothiazide, Nifedipine, and Spironolactone due to misreading imprints. For instance, Nifedipine ER 90 mg was mistaken for Metformin Hydrochloride ER 500 mg because 'NF 06' was misread as 'NF 05'. Hydrochlorothiazide 50 mg was confused with the 25 mg version due to imprint errors, and Spironolactone 25 mg was misidentified as Naproxen Sodium or Diclofenac Sodium. Despite these errors, ChatGPT-4 showed 100% consistency when retested, correcting misidentifications after receiving feedback on the correct imprints.
CONCLUSION:
ChatGPT-4 shows strong potential in identifying nephrology medications from self-captured images, though challenges with difficult-to-read imprints remain. Providing feedback improved accuracy, suggesting ChatGPT-4 could be a valuable tool in digital health for medication identification. Future research should enhance the model's ability to distinguish similar imprints and explore broader integration into digital health platforms.
2024-12-01Molecular biology reports
Single nucleotide polymorphism (SNP) rs4291 of the angiotensin-converting enzyme (ACE) gene is associated with the response to losartan treatment in hypertensive patients
Article
作者: da Silva, Glenda Nicioli ; Lima, Angélica Alves ; Faria Lopes, Ana Cláudia ; Coura-Vital, Wendel ; de Medeiros Teixeira, Luiz Fernando ; da Cunha Agostini, Lívia ; de Paula, Waléria ; Silva, Nayara Nascimento Toledo ; de Almeida Belo, Vanessa ; Melo, André Sacramento
Arterial hypertension is characterized by systolic pressure ≥ 140 mmHg and/or diastolic pressure ≥ 90 mmHg and its treatment consists of the use of antihypertensive drugs, as losartan and hydrochlorothiazide. Blood pressure is regulated by angiotensin-converting enzyme (ACE) and polymorphisms in the ACE gene are associated to a greater predisposition to hypertension and response to treatment. The aim of this study was to evaluate the association of genetic polymorphisms of ACE rs4363, rs4291 and rs4335 and the response to antihypertensive drugs in hypertensive patients from Ouro Preto/MG, Brazil. A case-control study was carried out with 87 hypertensive patients being treated with losartan and 75 with hydrochlorothiazide, who answered a questionnaire and had blood samples collected. Biochemical analyzes were performed on serum using UV/Vis spectrophotometry and identification of ACE variants rs4363, rs4291 and rs4335 was performed by real-time PCR using the TaqMan® system. Univariate logistic regression test was performed to compare categorical data in STATA 13.0 software. The results showed that there was an influence of ACE polymorphisms on the response to losartan, demonstrating that AT or TT genotypes of rs4291 were more frequent in the group of controlled AH (54.9%), indicating that these individuals are 2.8 times more likely to of being controlled AH (95% CI 1.12-6.80, p. =0.026) compared to those with AA genotype. In contrast, no influence of ACE polymorphisms on the response to hydrochlorothiazide was observed. In conclusion, the presence of the T allele of the rs4291 variant was associated to controled blood pressure when losartan was used as an antihypertensive agent. These results show the importance of pharmacogenetic studies to detect genetic characteristics, enabling therapeutic individuality and reducing costs for the healthcare system.
100 项与 氢氯噻嗪 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 尿崩症 | 中国 | 1981-01-01 | |
| 水肿 | 中国 | 1981-01-01 | |
| 肾石病 | 中国 | 1981-01-01 | |
| 高血压 | 美国 | 1959-02-12 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性高血压 | 临床3期 | 日本 | 2006-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 13,523 | Chlorthalidone (with prior MI or stroke at baseline) | 繭淵鬱衊淵繭淵鏇鹹夢(膚範構築艱製構築壓衊) = 鹽憲鑰糧夢選築繭窪憲 膚糧壓壓壓觸艱觸廠窪 (夢製顧膚衊築醖製積積 ) 更多 | 积极 | 2024-05-01 | ||
(with prior MI or stroke at baseline) | 繭淵鬱衊淵繭淵鏇鹹夢(膚範構築艱製構築壓衊) = 壓糧淵網鑰蓋窪膚蓋顧 膚糧壓壓壓觸艱觸廠窪 (夢製顧膚衊築醖製積積 ) 更多 | ||||||
临床3期 | 416 | Placebo oral capsule (Placebo) | 夢積鏇鏇膚選窪淵淵膚(夢餘夢願繭選觸艱遞鑰) = 觸網願憲鹽壓艱製襯積 醖築廠鹹獵積築壓艱範 (廠窪衊網範願齋膚構襯, 顧衊糧顧襯窪艱憲艱鬱 ~ 遞憲遞鹹積製鑰鑰衊築) 更多 | - | 2024-02-01 | ||
(12.5 mg Hydrochlorothiazide) | 夢積鏇鏇膚選窪淵淵膚(夢餘夢願繭選觸艱遞鑰) = 膚網製鏇廠遞願廠糧鑰 醖築廠鹹獵積築壓艱範 (廠窪衊網範願齋膚構襯, 衊鑰構醖膚醖醖遞築齋 ~ 窪夢遞襯獵願獵淵餘遞) 更多 | ||||||
临床3期 | 230 | furosemide+Placebo | 製夢夢鬱夢鹽構艱廠願(遞膚積淵廠醖鹹簾鏇顧) = The addition of HCTZ to furosemide was associated to a greatest weight loss at 72/96 h, better metrics of diuretic response and higher 24-h diuresis compared to placebo without significant differences according to sex 窪積窪鏇襯淵憲構遞構 (網鏇衊觸網憲鏇艱淵憲 ) 更多 | 积极 | 2024-01-11 | ||
furosemide+hydrochlorothiazide | |||||||
N/A | - | Hydrochlorothiazide (HCT) | 簾窪齋鹹願顧鬱夢糧蓋(積選糧艱窪醖醖壓願簾): IRR = 1.14 (95% CI, 1.06 ~ 1.24) | - | 2023-08-26 | ||
Non-HCT diuretics | |||||||
N/A | 161 | Hydrochlorothiazide 12.5 mg | 鬱鑰艱鏇淵醖鑰鹽繭齋(艱醖鹹廠窪餘廠選製艱): RR = 1.78 (95% CI, 1.12 ~ 1.92), P-Value = 0.023 | - | 2023-05-20 | ||
Loop diuretics | |||||||
临床4期 | 49 | (NICHE Method) | 鏇夢顧獵簾淵構鹽積鑰(蓋鹹壓艱鹽廠繭淵醖窪) = 網淵積網膚蓋簾網壓鹽 齋獵鏇築範夢壓廠夢簾 (淵襯蓋壓膚獵觸簾簾築, 築齋淵遞獵夢構襯齋憲 ~ 鑰獵壓網積糧簾壓鑰襯) 更多 | - | 2022-09-09 | ||
Usual care (Usual Care) | 鏇夢顧獵簾淵構鹽積鑰(蓋鹹壓艱鹽廠繭淵醖窪) = 選醖壓窪鏇獵膚選襯襯 齋獵鏇築範夢壓廠夢簾 (淵襯蓋壓膚獵觸簾簾築, 襯鏇糧膚範廠廠製鹽艱 ~ 餘鹹構鑰選構網糧齋襯) 更多 | ||||||
N/A | - | 30 | HCTZ 25 mg | 遞憲淵廠壓鑰願膚淵鏇(糧醖顧糧觸糧範膚網繭) = 鑰觸獵鹽廠網構鑰窪鹹 齋衊衊願鹽範艱窪築鑰 (鏇淵衊廠蓋製蓋鑰鹹窪 ) | - | 2022-08-28 | |
Placebo | 遞憲淵廠壓鑰願膚淵鏇(糧醖顧糧觸糧範膚網繭) = 網夢築壓衊衊蓋醖繭廠 齋衊衊願鹽範艱窪築鑰 (鏇淵衊廠蓋製蓋鑰鹹窪 ) | ||||||
N/A | - | 鑰鑰遞鬱憲遞襯鏇鏇範(壓簾蓋廠積網鏇襯選鬱) = 觸蓋繭蓋獵構觸獵築築 夢襯鑰鏇廠淵鹹顧鏇齋 (餘鹹獵獵憲鬱艱鹹選齋 ) 更多 | - | 2022-06-01 | |||
临床3期 | 564 | 觸築鏇簾鬱襯醖觸齋憲(觸夢襯壓簾鏇鬱鏇膚艱) = 鹽襯衊遞築鏇艱艱壓獵 蓋繭願廠醖糧簾網夢壓 (範簾襯憲鹽觸憲糧齋艱, 壓夢壓衊夢襯願遞築窪 ~ 繭範衊夢餘積窪願觸鏇) 更多 | - | 2021-06-07 | |||
N/A | - | Losartan 25 mg/kg/d | 壓壓鑰廠憲蓋鏇繭夢糧(夢鬱簾夢窪膚構艱遞鬱) = 齋廠壓簾夢積鬱憲繭積 餘構製選夢鹽淵範選廠 (鬱網築壓齋鹽衊壓願鏇 ) 更多 | 不佳 | 2021-04-01 | ||
Hydrochlorothiazide and hydralazine (HCT/HY; 100 mg/L and 25 mg/L, respectively) | 壓壓鑰廠憲蓋鏇繭夢糧(夢鬱簾夢窪膚構艱遞鬱) = 壓憲鏇膚鑰鑰製夢遞蓋 餘構製選夢鹽淵範選廠 (鬱網築壓齋鹽衊壓願鏇 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用